Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors

  • Published on 03/28/2024
  •  Reading time: 5 min.

Shijubou Naoki 1,2, Sumi Toshiyuki 2,3, Kubo Terufumi 1, Sasaki Kenta 1, Tsukahara Tomohide 1, Kanaseki Takayuki 1, Murata Kenji 1, Keira Yoshiko 4, Terai Kotomi 4, Ikeda Tatsuru 4, Yamada Yuichi 3, Chiba Hirofumi 2, Hirohashi Yoshihiko 1, Torigoe Toshihiko 1

1 Department of Pathology Sapporo Medical University School of Medicine 060-8556 Sapporo Japan
2 Department of Respiratory Medicine and Allergology Sapporo Medical University School of Medicine Sapporo Hokkaido Japan
3 Department of Respiratory Medicine Hakodate Goryoukaku Hospital Hakodate Hokkaido Japan
4 Department of Pathology Hakodate Goryoukaku Hospital Hakodate Hokkaido Japan


Purpose Although immune checkpoint inhibitors (ICIs), together with cytotoxic chemotherapy (chemoimmunotherapy), have been adapted for the initial treatment of extensive-disease small-cell lung cancer (ED-SCLC), they have achieved limited success. In ED-SCLC, a subtype of SCLC, the expression of immune-related molecules and clinical data are not well understood in relation to ICI treatment efficiency.
Methods We examined lung biopsy specimens from patients...


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Oncology

Receive our newsletter to stay up to date with the latest news in Oncology

More articles

From peer-reviewed journals in Oncology